Trial Profile
Phase I Study of Tolerance and Pharmacokinetics of TQ-B3139 in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs TQ B3139 (Primary)
- Indications Brain metastases; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 05 Aug 2022 Results published in the European Journal of Cancer
- 31 May 2020 Status changed to completed, results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology